Most Recent Articles about INCY
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Incyte Begins Phase III Study for Treatment of Duct Cancer Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

Related Companies

Name Exchange Price Mkt Cap
EXAS Exact Sciences Corporation NASDAQ $73.32 $9B
ICLR ICON plc NASDAQ $145.39 $7.9B
PRAH PRA Health Sciences, Inc. NASDAQ $108.16 $6.96B
CRL Charles River Laboratories International, Inc. NYSE $129.19 $6.21B
SYNH Syneos Health, Inc. NASDAQ $47.15 $4.85B
Sector: Health Care > Industry: Biotechnology: Commercial Physical & Biological Resarch